Bax低表达预测胶质瘤患者根治性切除及放化疗后不良临床结局
该研究用免疫组化检测96例胶质瘤根治性切除后患者的Bax蛋白表达,分析其与总生存(OS)和无复发生存(RFS)的关系。Bax低表达与更差OS(连续P=0.025;分类P=0.003)及RFS(连续P=0.014;分类P<0.0001)相关,且与胶质瘤分级负相关。作者提出Bax蛋白水平可作为风险分层的预后标志物。
要点
- Bax低表达与胶质瘤患者更差OS和RFS相关。
- Bax表达水平与胶质瘤分级呈负相关。
- 作者提出Bax蛋白水平可用于胶质瘤术后放化疗患者的风险分层。
核心结论
- Bax表达降低与胶质瘤患者不良临床结局相关,作者提出Bax蛋白水平可作为根治性切除及放化疗后胶质瘤患者风险分层的可靠预后标志物。
研究设计与样本
- 采用免疫组化法检测96例胶质瘤患者根治性切除后的Bax蛋白表达。
- 进行独立连续分析和多变量分类分析,分类分析采用测试集/验证集定义的切点。
- 采用Kaplan-Meier法估计总生存(OS)和无复发生存(RFS)。
主要发现
- 胶质母细胞瘤中Bax蛋白水平较II级胶质瘤显著降低。
- Bax低表达者OS更差(连续P=0.025;分类P=0.003)且RFS更差(连续P=0.014;分类P<0.0001)。
- Bax表达水平与胶质瘤分级呈负相关。
- 接受放疗后手术切除的患者OS(中位45 vs 17个月)和RFS(中位39 vs 16个月)显著增加。
- Bax水平较高且接受放疗的患者生存率大幅提高(中位OS=66个月,中位RFS=105个月)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognosis in patients with gliomas after surgical resection followed by radiotherapy and/or chemotherapy is still very poor. The pro-apoptotic protein Bax, a short-lived protein in cancers, plays important roles in the sensitivity of glioma cells to spontaneous and therapy-induced apoptosis but and its prognostic value in gliomas is unknown. METHODS: By an immunohistochemical method, we determined Bax protein expression from 96 patients with gliomas after curative resection. Two statistical analyses were performed to evaluate the prognostic significance of Bax protein: an independent continuous and a multivariate categorical analysis, with test/validation set-defined cut points, and Kaplan-Meier estimated outcome measures of overall survival (OS) and relapse-free survival (RFS). RESULTS: Bax protein levels in glioblastoma were significantly decreased compared with grade II gliomas. Lower levels of Bax expression confer worse OS (continuous P = 0.025; categorical P = 0.003) and RFS (continuous P = 0.014; categorical P < 0.0001) and negatively correlate with the grades of gliomas. Patients underwent radiotherapy followed by surgical resection showed significantly increased OS (median = 45 vs. 17 months) and RFS (median = 39 vs. 16 months). Patients with higher levels of Bax and radiotherapy showed greatly increased survival rates (median OS = 66 months and median RFS = 105 months). Lower expression of Bax also confers inferior clinical outcome for gliomas patients after chemotherapy with temozolomide (OS and RFS P < 0.0001). CONCLUSION: Decreased expression of Bax correlates with poor clinical outcome in patients with gliomas. We propose that Bax protein levels can be used as a reliable prognostic marker for risk-stratify patients with gliomas after curative resection and radiotherapy and/or chemotherapy.
引用
- Wang PG, Li YT, Pan Y, et al. Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy. J Neurooncol. 2018. PMID: 30446901. doi:10.1007/s11060-018-03031-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。